Cargando…
Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study
BACKGROUND: Diabetic nephropathy (DN) is characterized by albuminuria, hypertension, and a progressive decline in glomerular filtration rate. The 3-hydroxy-3-methylglutaryl coenzyme A is a well-known agent that is active in lowering total plasma and low-density lipoprotein cholesterol (LDL-C) levels...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036295/ https://www.ncbi.nlm.nih.gov/pubmed/27833243 http://dx.doi.org/10.4103/0300-1652.190600 |
_version_ | 1782455533862649856 |
---|---|
author | Sadighi, Alireza Safa, Javid Vatankhah, Amir-Mansour Ghorashi, Sona Aharilahagh, Aida Davari-Farid, Sina Nezami-Nargabad, Ourmaan Naghavi-Behzad, Mohammad Piri, Reza Pishahang, Parinaz Babapoor-Farrokhran, Savalan Fakour, Sanam Ghodratnezhad-Azar, Nastaran |
author_facet | Sadighi, Alireza Safa, Javid Vatankhah, Amir-Mansour Ghorashi, Sona Aharilahagh, Aida Davari-Farid, Sina Nezami-Nargabad, Ourmaan Naghavi-Behzad, Mohammad Piri, Reza Pishahang, Parinaz Babapoor-Farrokhran, Savalan Fakour, Sanam Ghodratnezhad-Azar, Nastaran |
author_sort | Sadighi, Alireza |
collection | PubMed |
description | BACKGROUND: Diabetic nephropathy (DN) is characterized by albuminuria, hypertension, and a progressive decline in glomerular filtration rate. The 3-hydroxy-3-methylglutaryl coenzyme A is a well-known agent that is active in lowering total plasma and low-density lipoprotein cholesterol (LDL-C) levels in cases with hypercholesterolemia. Hence, in this study, proteinuria changes at the beginning and after the withdrawal of lovastatin in patients with type 2 DN (T2DN) were studied. MATERIALS AND METHODS: Lovastatin was administered for thirty male patients with T2DN and then was withdrawn. Twenty-four hours, urine creatinine and protein levels were determined. RESULTS: The mean levels of total cholesterol and LDL-C were reduced without any change in the triglyceride (TG) level while the high-density lipoprotein cholesterol (HDL-C) level was increased. There was a reverse linear correlation between the changes in the level of HDL-C and the changes in the level of 24 h urine protein after 90 days of lovastatin therapy (P = 0.007, r = −0.484). CONCLUSIONS: Short-term 3-month lovastatin therapy has no effect on proteinuria levels in patients with T2DN despite the antihyperlipidemic effects and reverse correlation of proteinuria with HDL-C. |
format | Online Article Text |
id | pubmed-5036295 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Medknow Publications & Media Pvt Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-50362952016-11-10 Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study Sadighi, Alireza Safa, Javid Vatankhah, Amir-Mansour Ghorashi, Sona Aharilahagh, Aida Davari-Farid, Sina Nezami-Nargabad, Ourmaan Naghavi-Behzad, Mohammad Piri, Reza Pishahang, Parinaz Babapoor-Farrokhran, Savalan Fakour, Sanam Ghodratnezhad-Azar, Nastaran Niger Med J Original Article BACKGROUND: Diabetic nephropathy (DN) is characterized by albuminuria, hypertension, and a progressive decline in glomerular filtration rate. The 3-hydroxy-3-methylglutaryl coenzyme A is a well-known agent that is active in lowering total plasma and low-density lipoprotein cholesterol (LDL-C) levels in cases with hypercholesterolemia. Hence, in this study, proteinuria changes at the beginning and after the withdrawal of lovastatin in patients with type 2 DN (T2DN) were studied. MATERIALS AND METHODS: Lovastatin was administered for thirty male patients with T2DN and then was withdrawn. Twenty-four hours, urine creatinine and protein levels were determined. RESULTS: The mean levels of total cholesterol and LDL-C were reduced without any change in the triglyceride (TG) level while the high-density lipoprotein cholesterol (HDL-C) level was increased. There was a reverse linear correlation between the changes in the level of HDL-C and the changes in the level of 24 h urine protein after 90 days of lovastatin therapy (P = 0.007, r = −0.484). CONCLUSIONS: Short-term 3-month lovastatin therapy has no effect on proteinuria levels in patients with T2DN despite the antihyperlipidemic effects and reverse correlation of proteinuria with HDL-C. Medknow Publications & Media Pvt Ltd 2016 /pmc/articles/PMC5036295/ /pubmed/27833243 http://dx.doi.org/10.4103/0300-1652.190600 Text en Copyright: © 2016 Nigerian Medical Journal http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. |
spellingShingle | Original Article Sadighi, Alireza Safa, Javid Vatankhah, Amir-Mansour Ghorashi, Sona Aharilahagh, Aida Davari-Farid, Sina Nezami-Nargabad, Ourmaan Naghavi-Behzad, Mohammad Piri, Reza Pishahang, Parinaz Babapoor-Farrokhran, Savalan Fakour, Sanam Ghodratnezhad-Azar, Nastaran Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study |
title | Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study |
title_full | Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study |
title_fullStr | Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study |
title_full_unstemmed | Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study |
title_short | Short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: A clinical trial study |
title_sort | short-term effects of lovastatin therapy on proteinuria of type 2 diabetic nephropathy: a clinical trial study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036295/ https://www.ncbi.nlm.nih.gov/pubmed/27833243 http://dx.doi.org/10.4103/0300-1652.190600 |
work_keys_str_mv | AT sadighialireza shorttermeffectsoflovastatintherapyonproteinuriaoftype2diabeticnephropathyaclinicaltrialstudy AT safajavid shorttermeffectsoflovastatintherapyonproteinuriaoftype2diabeticnephropathyaclinicaltrialstudy AT vatankhahamirmansour shorttermeffectsoflovastatintherapyonproteinuriaoftype2diabeticnephropathyaclinicaltrialstudy AT ghorashisona shorttermeffectsoflovastatintherapyonproteinuriaoftype2diabeticnephropathyaclinicaltrialstudy AT aharilahaghaida shorttermeffectsoflovastatintherapyonproteinuriaoftype2diabeticnephropathyaclinicaltrialstudy AT davarifaridsina shorttermeffectsoflovastatintherapyonproteinuriaoftype2diabeticnephropathyaclinicaltrialstudy AT nezaminargabadourmaan shorttermeffectsoflovastatintherapyonproteinuriaoftype2diabeticnephropathyaclinicaltrialstudy AT naghavibehzadmohammad shorttermeffectsoflovastatintherapyonproteinuriaoftype2diabeticnephropathyaclinicaltrialstudy AT pirireza shorttermeffectsoflovastatintherapyonproteinuriaoftype2diabeticnephropathyaclinicaltrialstudy AT pishahangparinaz shorttermeffectsoflovastatintherapyonproteinuriaoftype2diabeticnephropathyaclinicaltrialstudy AT babapoorfarrokhransavalan shorttermeffectsoflovastatintherapyonproteinuriaoftype2diabeticnephropathyaclinicaltrialstudy AT fakoursanam shorttermeffectsoflovastatintherapyonproteinuriaoftype2diabeticnephropathyaclinicaltrialstudy AT ghodratnezhadazarnastaran shorttermeffectsoflovastatintherapyonproteinuriaoftype2diabeticnephropathyaclinicaltrialstudy |